Patent: 10,035,817
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,035,817
Title: | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
Abstract: | The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate. |
Inventor(s): | Chen; Xiaoxi Kevin (Natick, MA), Li; Xinfang (Newton, MA) |
Assignee: | IMMUNOGEN, INC. (Waltham, MA) |
Application Number: | 14/430,701 |
Patent Claims: | see list of patent claims |
Details for Patent 10,035,817
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2032-10-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2032-10-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2032-10-04 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | See Plans and Pricing | 2032-10-04 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2032-10-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |